您現在的位置: > Language Tips > Audio & Video > Special Speed News  
     





      Once-daily pill could simplify HIV treatment
    [ 2006-02-06 15:57 ]


    I’m Steve Ember with the VOA Special English Health Report.


    Myers Squibb and Gilead Sciences have combined many H.I.V. drugs into a single pill
    Sometimes the best medicine is more than one kind of medicine. Malaria, tuberculosis and H.I.V./AIDS, for example, are all treated with combinations of drugs.

    But that can mean a lot of pills to take. It would be simpler if drug companies combined all the medicines into a single pill, taken just once a day.

    Now, two companies say they have done that for people just starting treatment for H.I.V., the virus that causes AIDS. The companies are Bristol-Myers Squibb and Gilead Sciences.

    They have developed a single pill that combines three drugs currently on the market. Bristol-Myers Squibb sells one of them under the name Sustiva. Gilead combined the others, Emtriva and Viread, into a single pill in two thousand four.

    Combining drugs involves more than technical issues. It also involves issues of competition if the drugs are made by different companies. The new once-daily pill is the result of what is described as the first joint venture agreement of its kind in the treatment of H.I.V.

    In January the New England Journal of Medicine published a study of the new pill. Researchers compared its effectiveness to that of the widely used combination of Sustiva and Combivir. Combivir contains two drugs, AZT and 3TC. The researchers say that after one year of treatment, the new pill suppressed H.I.V. levels in more patients and with fewer side effects.

    Gilead paid for the study. Professor Joel Gallant at the Johns Hopkins School of Medicine in Baltimore, Maryland, led the research. He is a paid adviser to Gilead and Bristol-Meyers Squibb as well as the maker of Combivir, GlaxoSmithKline.

    GlaxoSmithKline reacted to the findings by saying that a single study is of limited value. It says the effectiveness of Combivir has been shown in each of more than fifty studies.

    The price of the new once-daily pill has not been announced. But Gilead and Bristol-Myers Squibb say they will provide it at reduced cost to developing countries.

    They plan in the next few months to ask the United States Food and Drug Administration to approve the new pill.

    There are limits to who could take it because of the different drugs it contains. For example, pregnant women are told not to take Sustiva because of the risk of birth disorders.

    Experts say more than forty million people around the world are living with H.I.V.

    This VOA Special English Health Report was written by Cynthia Kirk. Read and listen to our reports at voaspecialenglish.com. I’m Steve Ember.

    Vocabulary

     

     

     
     
     




    最近新中文字幕大全高清| 久久久久亚洲Av无码专| 国产亚洲3p无码一区二区| 亚洲欧美日韩国产中文| 久久无码av三级| 国产成人无码AⅤ片在线观看| 亚洲中文字幕无码一区| 精品国产毛片一区二区无码| 中文无码成人免费视频在线观看| 最近高清中文字幕免费| 无码AV动漫精品一区二区免费| 无码国内精品久久人妻蜜桃| 久久亚洲AV成人无码软件| 中文字幕亚洲免费无线观看日本| 无码高清不卡| av无码播放一级毛片免费野外| 亚洲va无码专区国产乱码| 少妇性饥渴无码A区免费| 中文字幕免费在线观看| 中文字幕乱码一区二区免费| 免费一区二区无码视频在线播放 | 中文字幕av无码一区二区三区电影| 国产精品亚洲аv无码播放| 亚洲国产一二三精品无码| 一本色道久久HEZYO无码| 中文字幕在线观看国产| 无码人妻少妇久久中文字幕 | 最近中文字幕精彩视频| 最近高清中文字幕免费| 日本一区二区三区精品中文字幕| 中文字幕日韩精品无码内射| 中文字幕理伦午夜福利片| 熟妇人妻中文a∨无码| 精品久久久中文字幕人妻| 亚洲欧美日韩中文播放| 中文亚洲AV片不卡在线观看| 精品一区二区三区中文字幕| 日韩电影免费在线观看中文字幕| 最近中文字幕大全中文字幕免费 | 四虎影视无码永久免费| 国产台湾无码AV片在线观看|